Novozymes OneHealth Revenue and Competitors
Estimated Revenue & Valuation
- Novozymes OneHealth's estimated annual revenue is currently $28.5M per year.
- Novozymes OneHealth's estimated revenue per employee is $155,000
Employee Data
- Novozymes OneHealth has 184 Employees.
- Novozymes OneHealth grew their employee count by 37% last year.
Novozymes OneHealth's People
Name | Title | Email/Phone |
---|
Novozymes OneHealth Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7910M | 2784 | 6% | $204.3M | N/A |
#2 | $42.8M | 276 | 8% | N/A | N/A |
#3 | $3.4M | 1097 | -1% | $85.7M | N/A |
#4 | $13.2M | 12 | -77% | $263.3M | N/A |
#5 | $22.9M | 148 | 17% | N/A | N/A |
#6 | $3.6M | 23 | 10% | N/A | N/A |
#7 | $28.5M | 184 | 37% | N/A | N/A |
#8 | $1.6M | 10 | -17% | N/A | N/A |
#9 | $10.1M | 65 | 35% | N/A | N/A |
#10 | $9.1M | 59 | 59% | N/A | N/A |
What Is Novozymes OneHealth?
Novozymes OneHealth will help people live healthier and better lives by rethinking tomorrow within human health and finding the one-in-a-trillion verifiable biology-based solutions that can be proven to solve profound consumer health challenges related to modern lifestyles. Part of Novozymes Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we find biological answers to preserve the planet’s resources and help build better lives.
keywords:N/AN/A
Total Funding
184
Number of Employees
$28.5M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novozymes OneHealth News
That was the view of Dr Kimmo Makinen, Innovation Director at Novozymes OneHealth, who was speaking at the recent Probiota conference in...
... used as a marker for hydrolyzed PGN (Novozymes A/S Biologiens, Lyngby, Denmark). ... The European Union One Health 2019 Zoonoses Report.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $28.5M | 184 | 37% | N/A |
#2 | N/A | 195 | 17% | N/A |
#3 | $113.6M | 505 | 7% | N/A |